Gram Research analysis of a 2026 case report identified a hidden mutation in the PHEX gene that standard genetic tests couldn’t detect, using advanced whole genome and RNA sequencing. The mutation caused the patient’s body to waste phosphate and weaken bones. After diagnosis, the patient received Burosumab treatment and improved clinically. This case demonstrates that comprehensive genetic testing can solve diagnostic mysteries in rare diseases when traditional methods fail.
Researchers discovered a hidden genetic mutation in a woman with X-linked hypophosphatemia (XLH), a rare disease that weakens bones by preventing the body from properly using phosphate. The mutation was buried deep in the PHEX gene and couldn’t be found with standard genetic tests. Using advanced DNA and RNA sequencing technologies, scientists identified the problem and confirmed it was causing the disease. After diagnosis, the patient received a targeted treatment called Burosumab and improved significantly. This case shows how newer genetic testing methods can solve medical mysteries when traditional tests fail.
Key Statistics
A 2026 case report published in Frontiers in Endocrinology identified a deep intronic PHEX variant (c.2070 + 601C>T) using whole genome sequencing and RNA analysis in a patient with X-linked hypophosphatemia who had tested negative on standard genetic tests for years.
According to research reviewed by Gram, up to 16% of clinically diagnosed X-linked hypophosphatemia cases have no detectable mutation using standard sequencing approaches, highlighting the diagnostic gap that advanced genomic methods can address.
The identified deep intronic variant caused two aberrant transcripts with premature stop codons, demonstrating a loss-of-function mechanism that expanded the known PHEX mutation spectrum beyond previously characterized variants.
Following molecular diagnosis via advanced sequencing, the patient was successfully initiated on Burosumab therapy, resulting in documented clinical improvement and demonstrating the therapeutic value of genetic diagnosis in rare bone disease.
The Quick Take
- What they studied: Can advanced genetic testing find hidden mutations that cause rare bone disease when standard tests fail?
- Who participated: One female patient with X-linked hypophosphatemia who had clear symptoms of the disease but no genetic cause found after years of testing
- Key finding: Researchers found a previously undetectable mutation hidden deep within the PHEX gene using whole genome sequencing and RNA analysis. This mutation was causing the patient’s body to produce too much of a hormone that wastes phosphate through the kidneys.
- What it means for you: If you or a family member has been diagnosed with a rare genetic disease but genetic tests keep coming back negative, more advanced testing methods might finally provide answers. This could lead to proper treatment and symptom improvement.
The Research Details
This is a case report describing one patient’s medical journey. The patient had clear signs of X-linked hypophosphatemia (a disease affecting how the body handles phosphate and calcium), but standard genetic testing over several years found nothing wrong. Researchers decided to use more powerful genetic tools: whole genome sequencing (which reads the entire genetic code, not just the protein-coding parts) and RNA sequencing (which shows which genes are actually being used by cells). They extracted genetic material from the patient’s blood and used advanced technology called Nanopore sequencing to read long stretches of genetic code, which helped them spot the hidden mutation.
Standard genetic tests only look at the parts of genes that directly code for proteins. About 16% of people diagnosed with XLH have no detectable mutation using these standard methods. This case demonstrates that mutations can hide in the ‘junk DNA’ between genes, where they can still cause disease by disrupting how genes are processed. Using comprehensive testing methods catches these hidden mutations.
This is a single case report, which is the lowest level of scientific evidence. However, the findings are strengthened by: (1) confirmation using two different advanced sequencing methods, (2) proof that the mutation actually causes the disease by showing how it disrupts the gene’s function, (3) clinical improvement after treatment, and (4) the mutation being newly created (de novo), not inherited. The case is published in a peer-reviewed journal, but readers should understand this describes one patient, not a large study group.
What the Results Show
The research team identified a mutation in the PHEX gene at position c.2070 + 601C>T. This mutation was located in a deep intronic region—essentially hidden in the non-coding part of the gene that standard tests don’t examine. When the gene was processed in the patient’s cells, this mutation caused the gene to include extra, incorrect pieces of genetic code (called pseudoexons). These aberrant transcripts contained premature stop signals, meaning the PHEX protein was never fully made. Without functional PHEX protein, the patient’s body couldn’t properly regulate phosphate levels, leading to excessive phosphate loss through the kidneys and weak bones.
The mutation was confirmed to be de novo, meaning it was newly created in this patient and not inherited from either parent. After the genetic diagnosis was confirmed, the patient was started on Burosumab, a medication that targets the hormone FGF23 (which causes phosphate wasting). The patient showed clinical improvement following treatment initiation, demonstrating that identifying the genetic cause led directly to effective therapy.
This case expands the known spectrum of PHEX mutations. Previously, most identified mutations were in the protein-coding regions of the gene. This finding shows that deep intronic variants—mutations in the non-coding regions—can also cause XLH. The research aligns with growing recognition that standard exome sequencing misses 10-16% of genetic causes in clinically diagnosed XLH patients. This case supports the use of whole genome sequencing and RNA analysis as next-step diagnostic tools when standard testing fails.
This is a single case report, so findings cannot be generalized to all XLH patients or all rare genetic diseases. The study doesn’t tell us how common deep intronic PHEX variants are among undiagnosed XLH cases. The patient’s clinical improvement could be attributed to Burosumab treatment rather than the diagnostic process itself. Additionally, this case required access to advanced sequencing technologies that aren’t available everywhere, which limits practical application for many patients globally.
The Bottom Line
For patients with a clear clinical diagnosis of XLH but negative standard genetic testing: Consider requesting whole genome sequencing and RNA sequencing analysis (high confidence for this specific scenario). For healthcare providers: Re-evaluate patients with strong clinical diagnoses but negative genetic results using comprehensive genomic approaches (moderate confidence, based on expanding evidence). For general population: This finding doesn’t change recommendations for the general public, as XLH is extremely rare.
This research is most relevant to: (1) patients with XLH who haven’t received a genetic diagnosis despite testing, (2) families with undiagnosed rare genetic diseases, (3) genetic counselors and doctors specializing in rare diseases, and (4) researchers developing diagnostic approaches for rare genetic conditions. It’s less relevant to people without rare genetic diseases or those already diagnosed through standard testing.
The patient showed clinical improvement after starting Burosumab therapy, but the timeline for symptom resolution in XLH varies. Bone health improvements typically take months to years to become apparent. The diagnostic process itself (from advanced testing to treatment initiation) took time, but once the genetic cause was identified, appropriate treatment could begin immediately.
Frequently Asked Questions
What is X-linked hypophosphatemia and why is it hard to diagnose?
X-linked hypophosphatemia (XLH) is a rare genetic disease where the body can’t properly use phosphate, leading to weak bones and low energy. Standard genetic tests miss about 16% of cases because mutations can hide in non-coding regions of genes. Advanced sequencing methods can find these hidden mutations.
How did researchers find the mutation that standard tests missed?
Researchers used whole genome sequencing (reading the entire genetic code, not just protein-coding parts) and Nanopore RNA sequencing (which reads long genetic sequences). These advanced methods revealed a mutation buried deep in the PHEX gene that standard exome sequencing couldn’t detect.
Can this discovery help other patients with undiagnosed genetic diseases?
Yes, this case demonstrates that comprehensive genomic analysis can solve diagnostic mysteries in rare genetic diseases. Patients with clear symptoms but negative standard genetic tests may benefit from whole genome and RNA sequencing to identify hidden mutations and enable targeted treatment.
What treatment did the patient receive after diagnosis?
The patient received Burosumab, a medication that targets FGF23 (the hormone causing phosphate wasting). The patient showed clinical improvement after starting this targeted therapy, demonstrating how genetic diagnosis enables appropriate treatment selection.
Is this genetic mutation inherited or did it just happen?
The mutation was de novo, meaning it was newly created in this patient and not inherited from either parent. This explains why neither parent had the disease, even though the patient had a clear genetic cause for her condition.
Want to Apply This Research?
- For XLH patients: Track phosphate and calcium levels through regular blood tests, recording results monthly. Monitor bone pain or weakness on a 1-10 scale weekly. Document any changes in energy levels or physical activity tolerance.
- Users diagnosed with XLH through genetic testing should: (1) Set reminders for medication adherence if on Burosumab or other treatments, (2) Log dietary phosphate and calcium intake to understand food impacts, (3) Record exercise or physical activity to monitor bone strength improvements, (4) Schedule regular follow-up lab work and set reminders for appointments.
- Establish a long-term tracking system that records: monthly lab values (phosphate, calcium, alkaline phosphatase), quarterly symptom assessments, medication adherence rates, and annual imaging results if available. Share this data with your healthcare provider to monitor treatment effectiveness and adjust therapy as needed.
This article describes a single case report of one patient with X-linked hypophosphatemia. Case reports represent the lowest level of scientific evidence and cannot be generalized to all patients with this condition. If you or a family member has been diagnosed with XLH or suspect you may have this condition, consult with a qualified geneticist or endocrinologist for personalized medical advice. Do not use this information to self-diagnose or self-treat. Genetic testing and treatment decisions should only be made under professional medical supervision. The findings in this case may not apply to your specific situation.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.